the infants had watery diarrhoea and vomiting lasting for one to five days. This outbreak was uncommon in that it involved older children (aged > 3 years) and it occurred in the summer. Rotavirus was identified in 52% of 81 stool specimens, including 8 of 12 collected from children older than 3 years (6) . Rotaviruses expressed the common serotypes and no vaccine strains were identified (5) .
The United States Centers for Diseases Control and Prevention (CDC) opined that environmental exposures were the most likely cause of the outbreak, with heavy rains in the earlier months and subsequent flooding most likely causing faecal contamination of the water supply (5). The CDC also indicated that the deaths associated with acute gastroenteritis might have been attributable to inappropriate case management, as certain children received anti-emetic and antidiarrhoeal injections, which are not part of the standard diarrhoea management (5). Since then, annual seasonal epidemics of infant gastroenteritis due to the rotavirus have continued unabated in Jamaica, with 21 total reported deaths in 2003 and 23 deaths in 2004; there was also a summer peak seen in sentinel sites in 2005. The Ministry of Health has also reported that public health education of healthcare providers, parents and caregivers regarding the use of oral rehydration therapy can reduce the severity and mortality from diarrhoea during outbreaks of acute gastroenteritis (7).
New Rotavirus Vaccines
The extremely favourable results of two, international, industry-sponsored, clinical mega-trials of new rotavirus vaccines as published in the January 5, 2006 issue of the New England Journal of Medicine are therefore welcomed (8, 9) particularly in developing countries where the burden of rotavirus disease is high, such as in Jamaica. These two new rotavirus vaccines and the two clinical megatrials are compared in the Table.
Challenges for the Developing World
In these huge clinical mega-trials, both rotavirus vaccines clearly demonstrated an impressive safety profile against infant intussusception, with proven efficacy against infant rotavirus gastroenteritis, thereby reducing healthcare contacts and therefore the economic costs that maybe related to infant rotavirus gastroenteritis (8, 9) .
The issues for the developing world remain whether intussusception would become more evident if these vaccines are given to older children (as may be necessary in Jamaica come, especially as this relates to the potential of creating missed opportunities for immunizations in the first few months of life (about 8-9 total visits for immunizations would now be required in infancy). Evolving partnerships between these two Vaccine Manufacturers, the Global Alliance for Vaccines and Immunization, the World Health Organization, Pan American Organization and the Bill and Melinda Gates Foundation are welcomed, as plans are galvanized to roll out these vaccines to children in the developing world, where these products are desperately needed in the continued fight to eliminate infant gastroenteritis. The arrival of these two rotavirus vaccines represents the first meaningful step towards universal access to vaccines and control of infant rotavirus gastroenteritis, similar to the where epidemic cases in older children have been described after widespread flooding) and when given to children in larger numbers (11) . The right price will always be an issue to negotiate, although the cost-benefit ratio of eliminating infant rotavirus gastroenteritis from the developing world may well be worth any effort. Challenges of immunizing young infants who maybe immuno-suppressed from HIV/ AIDS (which is likely undiagnosed when infant immunizations begin at 6-10 weeks), malnutrition and tropical bacterial, viral and parasitic inter-current childhood illnesses may yet become evident. The potential challenges of administering two live viral vaccines (rotavirus and oral polio vaccine) in a staggered manner to infants in the developing world, such as Jamaica, will need to be over- 
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